





AUM USD1.5+B | **per share NAV USD 1.7**  
 29 Portfolio Companies | **14 IPOs**

Release Date: May 15, 2026  
 Source: Market Observation Post System (MOPS) / Official Press Release  
 All figures in USD; FX: 1 USD = 31.995 TWD


### AUM Growth




### Earnings Driven by Investment Portfolio



### Liabilities & Equities



### NAV Profile USD\$1.7 per share (Market Value Basis)



### Core Business Investments MOIC

Jacobio	Bao Pharma	Lumosa	Medeon	BioGend	Mycenax
16.81x	13.76x	4.68x	5.87x	0.74x	1.29x
<b>Avg. 7.19x</b>					

### Portfolio Highlights



1875.HK  
 Post-disposal Stake 28%→3.87%  
 Market Cap:~\$19M

- WuXi XDC Strategic Acquisition of BioDlink (Jan 2026)
- Acquired ≥60% stake at HK\$4/share (114% premium)
  - Recouped approximately NT\$3.35 billion, concluding a 15-year incubation cycle with a 1.47x MOIC.



6499.TWO  
 Stake 24%  
 Market Cap: ~\$67M

- Received US FDA 510(k) for Urocross Expander System (Mar 2026), entering the US Benign Prostatic Hyperplasia (BPH) market.
- Targeting 40M US patients as minimally invasive First Intervention Therapy (FIT).



2659.HK  
 Stake 12%  
 Market Cap:~\$465M

- The proprietary "Human Hyaluronidase for Injection" secured official NMPA approval on March 31.
- Facilitates subcutaneous delivery for large-molecule antibodies via enhanced drug permeability.